DOCSLIB.ORG

Intravta Deltorphin, but Not DPDPE, Induces Place Preference in Ethanoldrinking Rats

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Intravta Deltorphin, but Not DPDPE, Induces Place Preference in Ethanoldrinking Rats ALCOHOLISM:CLINICAL AND EXPERIMENTAL RESEARCH Vol. 38, No. 1 January 2014 Intra-VTA Deltorphin, But Not DPDPE, Induces Place Preference in Ethanol-Drinking Rats: Distinct DOR-1 and DOR-2 Mechanisms Control Ethanol Consumption and Reward Jennifer M. Mitchell, Elyssa B. Margolis, Allison R. Coker, Daicia C. Allen, and Howard L. Fields Background: While there is a growing body of evidence that the delta opioid receptor (DOR) modu- lates ethanol (EtOH) consumption, development of DOR-based medications is limited in part because there are 2 pharmacologically distinct DOR subtypes (DOR-1 and DOR-2) that can have opposing actions on behavior. Methods: We studied the behavioral influence of the DOR-1-selective agonist [D-Pen2,D-Pen5]- Enkephalin (DPDPE) and the DOR-2-selective agonist deltorphin microinjected into the ventral tegmental area (VTA) on EtOH consumption and conditioned place preference (CPP) and the physio- logical effects of these 2 DOR agonists on GABAergic synaptic transmission in VTA-containing brain slices from Lewis rats. Results: Neither deltorphin nor DPDPE induced a significant place preference in EtOH-na€ıve Lewis rats. However, deltorphin (but not DPDPE) induced a significant CPP in EtOH-drinking rats. In con- trast to the previous finding that intra-VTA DOR-1 activity inhibits EtOH consumption and that this inhibition correlates with a DPDPE-induced inhibition of GABA release, here we found no effect of DOR-2 activity on EtOH consumption nor was there a correlation between level of drinking and deltorphin-induced change in GABAergic synaptic transmission. Conclusions: These data indicate that the therapeutic potential of DOR agonists for alcohol abuse is through a selective action at the DOR-1 form of the receptor. Key Words: Ethanol, Place Preference, Self-Administration, Delta Opioid Receptor, Reward. HERE ARE 4 distinct classes of opioid receptors: the tion, depending upon the behavioral state of the animal T mu opioid receptor (MOR), the delta opioid receptor (Mitchell et al., 2005; Walker and Koob, 2008). (DOR), the kappa opioid receptor (KOR), and the nocicep- The ventral tegmental area (VTA) is important for both tin receptor. There is evidence that endogenous opioids exert opioid reward and regulation of EtOH consumption in a strong regulatory action on ethanol (EtOH) consumption rodents. Alcohol-preferring rats self-administer EtOH in both humans and rodents and that selectively targeting (McBride et al., 1993) and its primary metabolite acetalde- each opioid receptor can either promote or inhibit EtOH hyde (Rodd-Henricks et al., 2002) directly into the VTA, and consumption. For example, MOR knockout mice drink less VTA cFOS expression increases after exposure to an EtOH- EtOH (Roberts et al., 2000), while DOR knockout mice associated context (Hill et al., 2007). Intra-VTA administra- drink more EtOH (Roberts et al., 2001). In addition, KOR tion of either the nonselective opioid-antagonist naltrexone antagonists can either promote or reduce EtOH consump- (Mitchell et al., 2009) or the MOR-selective antagonist CTOP reduces EtOH consumption in rats (Margolis et al., 2008), while intra-VTA administration of the DOR-antago- nist TIPP-Ψ increases EtOH consumption (Margolis et al., From the Ernest Gallo Clinic and Research Center (JMM, EBM, 2008). The nonselective opioid-antagonist methylnaloxoni- ARC, DCA, HLF), University of California, San Francisco, Emeryville, um also attenuates EtOH place preference in mice (Bechtholt California; and Department of Neurology (JMM, EBM, ARC, HLF), and Cunningham, 2005). University of California, San Francisco, California. Although there is only 1 gene encoding the DOR (Evans Received for publication January 30, 2013; accepted June 5, 2013. Reprint requests: Jennifer M. Mitchell, PhD, Ernest Gallo Clinic and et al., 1992; Simonin et al., 1994), there are 2 pharmacologi- Research Center, 5858 Horton Street, Suite #200, Emeryville, CA 94608; cally distinct classes of DOR ligands: DOR-1 and DOR-2, Tel.: 510-985-3921; Fax: 510-985-3101; E-mail: jennifer.mitchell@ucsf. both of which are blocked by the highly DOR-selective edu antagonist TIPP-Ψ (Schiller et al., 1993). The metabolically © Copyright 2013 by the Research Society on Alcoholism. stable enkephalin analog [D-Pen2,D-Pen5]-Enkephalin DOI: 10.1111/acer.12246 (DPDPE) is a highly selective DOR-1 agonist, while Alcohol Clin Exp Res, Vol 38, No 1, 2014: pp 195–203 195 196 MITCHELL ET AL. [D-Ala2]-Deltorphin II (deltorphin) is a highly selectively regulating reward and anxiety necessitates consideration of DOR-2 agonist (Fang et al., 1994; Horan et al., 1993; issues related to addiction and abuse liability. Therefore, it is Mattia et al., 1991; Vanderah et al., 1994). There is no cross- critical to determine whether these compounds are rewarding tolerance between these two DOR agonists (Sofuoglu et al., in ETOH-consuming animals. 1991a,b), and DOR-1 and DOR-2 ligands have different, Here, we used a conditioned place preference (CPP) para- sometimes opposing, effects on a variety of behaviors (Chur- digm to assess the rewarding effects of the DOR-1 agonist chill et al., 1995; Noble et al., 1996; van Rijn and Whistler, DPDPE and the DOR-2 agonist deltorphin in both EtOH- 2009; Yu and Bodnar, 1997). We previously reported that na€ıve and EtOH-drinking Lewis rats when administered into DOR-1 activation in the VTA of the rat decreases EtOH the VTA. We also examined the effects of the DOR-2 agonist consumption (Margolis et al., 2008). However, in mice, sys- deltorphin on VTA GABAA synaptic transmission to deter- temic administration of the DOR-2 antagonist, naltriben, mine whether the previously identified relationship between decreases EtOH consumption (van Rijn and Whistler, 2009), attenuated drinking and inhibition of GABA release in VTA suggesting opposing roles of DOR subtypes on drinking slices in response to a DOR-1 agonist would generalize to a behavior. To study the therapeutic potential of DOR ligands DOR-2 agonist. for alcohol abuse and related behavioral disorders, it is essen- tial to differentiate DOR-1 and DOR-2 effects on behavior MATERIALS AND METHODS and synaptic function in brain regions that contribute to reward. Animals We have previously shown that MOR and DOR-1 activity Sixty-one male Lewis rats (47 for behavioral experiments and 14 in the VTA has opposing effects on EtOH consumption. In for electrophysiology; Harlan Laboratories, Hayward, CA) weigh- contrast to the attenuation of EtOH consumption by intra- ing between 275 and 300 g on arrival were housed individually in a temperature-controlled colony room (21°C) on a 12-hour reversed VTA injection of the MOR-selective antagonist CTOP, light/dark cycle (lights off at 10:00 AM). For pharmacological stud- intra-VTA microinjection of the DOR-1 agonist DPDPE ies, all animals served as their own controls (within subjects design). decreases EtOH consumption through inhibition of GABA Additionally, each animal served in only a single pharmacology release in chronically drinking animals (Margolis et al., experiment (Fig. 1). Animals were all within the same age range at 2008). Furthermore, the DPDPE-induced presynaptic inhibi- the beginning of each experiment. All experiments were performed during the dark portion of the cycle. Rat chow and water were tion of GABA terminals is inversely correlated with EtOH available ad libitum throughout the experiment. During EtOH self- consumption (Margolis et al., 2008). However, the actions of administration periods (see below), 10% EtOH (v/v; Gold Shield, DOR-2 agonists on GABAergic synaptic transmission in Hayward, CA) was also available ad libitum. All experimental VTA neurons have not been studied. Further, although the protocols were approved by the Institutional Animal Care and Use evidence indicates that DOR ligands are potentially effective Committee and were conducted in accordance with the Guide for the Care and Use of Laboratory Animals (NIH). therapeutics for alcohol abuse, the involvement of DOR in Fig. 1. Experimental timeline for place preference behavior (n = 37), ethanol (EtOH)-drinking experiments (n = 10), and electrophysiology (n = 14). Animals always had access to EtOH and H2O bottles when not in the conditioned place preference (CPP) apparatus. DOR-1 AND DOR-2 EFFECTS ON ETOH REWARD 197 EtOH Self-Administration Animals were counterbalanced such that an equal number of ani- mals received drug injections in the black versus white box. Animals EtOH was self-administered via a 2-bottle continuous access, were tested for expression of CPP 1 day after the final conditioning free-choice paradigm in which 1 bottle contained 10% EtOH (v/v) session. and the other bottle contained water. Sucrose was never added to the EtOH solution. Animals were weighed daily, and the amount of EtOH and water consumed was measured at the same time each VTA Microinjections day (10:00 AM). Bottles were identical, and their positions were Each injection was made using a 1-ll syringe (Hamilton, Reno, counterbalanced and rotated daily. Animals were maintained on NV) attached to 20 cm of PE 50 tubing connected to a 33-gauge the 2-bottle choice paradigm for at least 12 weeks until consump- injection cannula (Plastics One). Microinjections of 0.5 llvolumes tion had stabilized (defined as <15% change in drinking over 3 day were given at a rate of 0.25 ll/min using a syringe pump (KD Scien- bins) before surgery and experimentation commenced. Similarly, tific, Holliston, MA) into each side of the VTA. Injection cannulae following surgery, behavioral training did not begin until drinking extended 1.5 to 2 mm beyond guide cannula to reach a depth of had returned to presurgical levels (defined as no significant differ- 9.0 mm and were left in place for 1 minute following microinjec- ence between presurgical 3 day bin and final postsurgical 3 day tions to minimize the backflow of drug solution. For CPP experi- bin). For place preference experiments, animals always had access ments, microinjections were made directly prior to placement of to EtOH and H O bottles when not in the CPP chambers.
Load more

Recommended publications
  • Evaluation of in Silico Approach for Prediction of Presence of Opioid Peptides in Wheat
    Evaluation of in silico approach for prediction of presence of opioid peptides in wheat This is the Accepted version of the following publication Garg, Swati, Apostolopoulos, Vasso, Nurgali, Kulmira and Mishra, Vijay Kumar (2018) Evaluation of in silico approach for prediction of presence of opioid peptides in wheat. Journal of Functional Foods, 41. 34 - 40. ISSN 1756-4646 The publisher’s official version can be found at https://www.sciencedirect.com/science/article/pii/S1756464617307454 Note that access to this version may require subscription. Downloaded from VU Research Repository https://vuir.vu.edu.au/36577/ 1 1 Evaluation of in silico approach for prediction of presence of opioid peptides in wheat 2 gluten 3 Abstract 4 Opioid like morphine and codeine are used for the management of pain, but are associated 5 with serious side-effects limiting their use. Wheat gluten proteins were assessed for the 6 presence of opioid peptides on the basis of tyrosine and proline within their sequence. Eleven 7 peptides were identified and occurrence of predicted sequences or their structural motifs were 8 analysed using BIOPEP database and ranked using PeptideRanker. Based on higher peptide 9 ranking, three sequences YPG, YYPG and YIPP were selected for determination of opioid 10 activity by cAMP assay against µ and κ opioid receptors. Three peptides inhibited the 11 production of cAMP to varied degree with EC50 values of YPG, YYPG and YIPP were 5.3 12 mM, 1.5 mM and 2.9 mM for µ-opioid receptor, and 1.9 mM, 1.2 mM and 3.2 mM for κ- 13 opioid receptor, respectively.
    [Show full text]
  • INVESTIGATION of NATURAL PRODUCT SCAFFOLDS for the DEVELOPMENT of OPIOID RECEPTOR LIGANDS by Katherine M
    INVESTIGATION OF NATURAL PRODUCT SCAFFOLDS FOR THE DEVELOPMENT OF OPIOID RECEPTOR LIGANDS By Katherine M. Prevatt-Smith Submitted to the graduate degree program in Medicinal Chemistry and the Graduate Faculty of the University of Kansas in partial fulfillment of the requirements for the degree of Doctor of Philosophy. _________________________________ Chairperson: Dr. Thomas E. Prisinzano _________________________________ Dr. Brian S. J. Blagg _________________________________ Dr. Michael F. Rafferty _________________________________ Dr. Paul R. Hanson _________________________________ Dr. Susan M. Lunte Date Defended: July 18, 2012 The Dissertation Committee for Katherine M. Prevatt-Smith certifies that this is the approved version of the following dissertation: INVESTIGATION OF NATURAL PRODUCT SCAFFOLDS FOR THE DEVELOPMENT OF OPIOID RECEPTOR LIGANDS _________________________________ Chairperson: Dr. Thomas E. Prisinzano Date approved: July 18, 2012 ii ABSTRACT Kappa opioid (KOP) receptors have been suggested as an alternative target to the mu opioid (MOP) receptor for the treatment of pain because KOP activation is associated with fewer negative side-effects (respiratory depression, constipation, tolerance, and dependence). The KOP receptor has also been implicated in several abuse-related effects in the central nervous system (CNS). KOP ligands have been investigated as pharmacotherapies for drug abuse; KOP agonists have been shown to modulate dopamine concentrations in the CNS as well as attenuate the self-administration of cocaine in a variety of species, and KOP antagonists have potential in the treatment of relapse. One drawback of current opioid ligand investigation is that many compounds are based on the morphine scaffold and thus have similar properties, both positive and negative, to the parent molecule. Thus there is increasing need to discover new chemical scaffolds with opioid receptor activity.
    [Show full text]
  • An Immortalized Myocyte Cell Line, HL-1, Expresses a Functional D
    J Mol Cell Cardiol 32, 2187–2193 (2000) doi:10.1006/jmcc.2000.1241, available online at http://www.idealibrary.com on An Immortalized Myocyte Cell Line, HL-1, Expresses a Functional -Opioid Receptor Claire L. Neilan1, Erin Kenyon1, Melissa A. Kovach1, Kristin Bowden1, William C. Claycomb2, John R. Traynor3 and Steven F. Bolling1 1Department of Cardiac Surgery, University of Michigan, B558 MSRB II, Ann Arbor, MI 48109-0686, USA, 2Department of Biochemistry and Molecular Biology, Louisiana State University Medical Center, New Orleans, LA 70112, USA and 3Department of Pharmacology, University of Michigan, 1301 MSRB III, Ann Arbor, MI 48109-0632, USA (Received 17 March 2000, accepted in revised form 30 August 2000, published electronically 25 September 2000) C. L. N,E.K,M.A.K,K.B,W.C.C,J.R.T S. F. B.An Immortalized Myocyte Cell Line, HL-1, Expresses a Functional -Opioid Receptor. Journal of Molecular and Cellular Cardiology (2000) 32, 2187–2193. The present study characterizes opioid receptors in an immortalized myocyte cell line, HL-1. Displacement of [3H]bremazocine by selective ligands for the mu (), delta (), and kappa () receptors revealed that only the -selective ligands could fully displace specific [3H]bremazocine binding, indicating the presence of only the -receptor in these cells. Saturation binding studies with the -antagonist naltrindole 3 afforded a Bmax of 32 fmols/mg protein and a KD value for [ H]naltrindole of 0.46 n. The binding affinities of various ligands for the receptor in HL-1 cell membranes obtained from competition binding assays were similar to those obtained using membranes from a neuroblastoma×glioma cell line, NG108-15.
    [Show full text]
  • Rubsicolins Are Naturally Occurring G-Protein-Biased Delta Opioid Receptor Peptides
    bioRxiv preprint doi: https://doi.org/10.1101/433805; this version posted October 5, 2018. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Title page Title: Rubsicolins are naturally occurring G-protein-biased delta opioid receptor peptides Short title: Rubsicolins are G-protein-biased peptides Authors: Robert J. Cassell1†, Kendall L. Mores1†, Breanna L. Zerfas1, Amr H.Mahmoud1, Markus A. Lill1,2,3, Darci J. Trader1,2,3, Richard M. van Rijn1,2,3 Author affiliation: 1Department of Medicinal Chemistry and Molecular Pharmacology, College of Pharmacy, 2Purdue Institute for Drug Discovery, 3Purdue Institute for Integrative Neuroscience, West Lafayette, IN 47907 †Robert J Cassell and Kendall Mores contributed equally to this work Corresponding author: ‡Richard M. van Rijn, Department of Medicinal Chemistry and Molecular Pharmacology, College of Pharmacy, Purdue University, West Lafayette, Indiana 47907 (Phone: 765-494- 6461; Email: [email protected]) Key words: delta opioid receptor; beta-arrestin; natural products; biased signaling; rubisco; G protein-coupled receptor Abstract: 187 Figures: 2 Tables: 2 References: 27 1 bioRxiv preprint doi: https://doi.org/10.1101/433805; this version posted October 5, 2018. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Abstract The impact that β-arrestin proteins have on G-protein-coupled receptor trafficking, signaling and physiological behavior has gained much appreciation over the past decade. A number of studies have attributed the side effects associated with the use of naturally occurring and synthetic opioids, such as respiratory depression and constipation, to excessive recruitment of β-arrestin.
    [Show full text]
  • Opioid Receptorsreceptors
    OPIOIDOPIOID RECEPTORSRECEPTORS defined or “classical” types of opioid receptor µ,dk and . Alistair Corbett, Sandy McKnight and Graeme Genes encoding for these receptors have been cloned.5, Henderson 6,7,8 More recently, cDNA encoding an “orphan” receptor Dr Alistair Corbett is Lecturer in the School of was identified which has a high degree of homology to Biological and Biomedical Sciences, Glasgow the “classical” opioid receptors; on structural grounds Caledonian University, Cowcaddens Road, this receptor is an opioid receptor and has been named Glasgow G4 0BA, UK. ORL (opioid receptor-like).9 As would be predicted from 1 Dr Sandy McKnight is Associate Director, Parke- their known abilities to couple through pertussis toxin- Davis Neuroscience Research Centre, sensitive G-proteins, all of the cloned opioid receptors Cambridge University Forvie Site, Robinson possess the same general structure of an extracellular Way, Cambridge CB2 2QB, UK. N-terminal region, seven transmembrane domains and Professor Graeme Henderson is Professor of intracellular C-terminal tail structure. There is Pharmacology and Head of Department, pharmacological evidence for subtypes of each Department of Pharmacology, School of Medical receptor and other types of novel, less well- Sciences, University of Bristol, University Walk, characterised opioid receptors,eliz , , , , have also been Bristol BS8 1TD, UK. postulated. Thes -receptor, however, is no longer regarded as an opioid receptor. Introduction Receptor Subtypes Preparations of the opium poppy papaver somniferum m-Receptor subtypes have been used for many hundreds of years to relieve The MOR-1 gene, encoding for one form of them - pain. In 1803, Sertürner isolated a crystalline sample of receptor, shows approximately 50-70% homology to the main constituent alkaloid, morphine, which was later shown to be almost entirely responsible for the the genes encoding for thedk -(DOR-1), -(KOR-1) and orphan (ORL ) receptors.
    [Show full text]
  • Receptor Types
    Proc. Natl. Acad. Sci. USA Vol. 87, pp. 3180-3184, April 1990 Pharmacology Chimeric opioid peptides: Tools for identifying opioid receptor types (dynorphin/dermorphin/deltorphin/monoclonal antibody/panning) Guo-xi XIE*t, ATSUSHI MIYAJIMA*, TAKASHI YOKOTA*, KEN-ICHI ARAI*, AND AVRAM GOLDSTEINt *Department of Molecular Biology, DNAX Research Institute of Molecular and Cellular Biology, Palo Alto, CA 94304; and tDepartment of Pharmacology, Stanford University, Stanford, CA 94305 Contributed by Avram Goldstein, January 23, 1990 ABSTRACT We synthesized several chimeric peptides in was assumed that the C-terminal amide group ofdermorphin, which the N-terminal nine residues of dynorphin-32, a peptide deltorphins, and DSLET and the alcohol group of DAGO selective for the K opioid receptor, were replaced by opioid could be removed without affecting opioid binding. By anal- peptides selective for other opioid receptor types. Each chi- ogy to dyn-32, which binds selectively to K opioid sites, meric peptide retained the high affminty and type selectivity DAGO-DYN and dermorphin-DYN should bind selectively characteristic of its N-terminal sequence. The common C- to p.; deltorphins-DYN and DSLET-DYN should bind selec- terminal two-thirds of the chimeric peptides served as an tively to 8. mAbs 17.M and 39 should act as nonblocking epitope recognized by the same monoclonal antibody. When antibodies to all these peptides. bound to receptors on a cell surface or membrane preparation, In the present study, we have demonstrated that the these peptides could still bind specifically to the monoclonal chimeric peptides do maintain the high affinities and type antibody. These chimeric peptides should be useful for isolating selectivities of their N-terminal sequences.
    [Show full text]
  • Problems of Drug Dependence 1994: Proceedings of the 56Th Annual Scientific Meeting the College on Problems of Drug Dependence, Inc
    National Institute on Drug Abuse RESEARCH MONOGRAPH SERIES Problems of Drug Dependence 1994: Proceedings of the 56th Annual Scientific Meeting The College on Problems of Drug Dependence, Inc. Volume I 152 U.S. Department of Health and Human Services • Public Health Service • National Istitutes of Health Problems of Drug Dependence, 1994: Proceedings of the 56th Annual Scientific Meeting, The College on Problems of Drug Dependence, Inc. Volume I: Plenary Session Symposia and Annual Reports Editor: Louis S. Harris, Ph.D. NIDA Research Monograph 152 1995 U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Public Health Service National Institutes of Health National Institute on Drug Abuse 5600 Fishers Lane Rockville, MD 20857 ACKNOWLEDGMENT The College on Problems of Drug Dependence, Inc., an independent, nonprofit organization, conducts drug testing and evaluations for academic institutions, government, and industry. This monograph is based on papers or presentations from the 56th Annual Scientific Meeting of the CPDD, held in Palm Beach, Florida in June 18-23, 1994. In the interest of rapid dissemination, it is published by the National Institute on Drug Abuse in its Research Monograph series as reviewed and submitted by the CPDD. Dr. Louis S. Harris, Department of Pharmacology and Toxicology, Virginia Commonwealth University was the editor of this monograph. COPYRIGHT STATUS The National Institute on Drug Abuse has obtained permission from the copyright holders to reproduce certain previously published material as noted in the text. Further reproduction of this copyrighted material is permitted only as part of a reprinting of the entire publication or chapter. For any other use, the copyright holder’s permission is required.
    [Show full text]
  • Efficacy and Safety of Gluten-Free and Casein-Free Diets Proposed in Children Presenting with Pervasive Developmental Disorders (Autism and Related Syndromes)
    FRENCH FOOD SAFETY AGENCY Efficacy and safety of gluten-free and casein-free diets proposed in children presenting with pervasive developmental disorders (autism and related syndromes) April 2009 1 Chairmanship of the working group Professor Jean-Louis Bresson Scientific coordination Ms. Raphaëlle Ancellin and Ms. Sabine Houdart, under the direction of Professor Irène Margaritis 2 TABLE OF CONTENTS Table of contents ................................................................................................................... 3 Table of illustrations .............................................................................................................. 5 Composition of the working group ......................................................................................... 6 List of abbreviations .............................................................................................................. 7 1 Introduction .................................................................................................................... 8 1.1 Context of request ................................................................................................... 8 1.2 Autism: definition, origin, practical implications ........................................................ 8 1.2.1 Definition of autism and related disorders ......................................................... 8 1.2.2 Origins of autism .............................................................................................. 8 1.1.2.1 Neurobiological
    [Show full text]
  • Blockade of O-Opioid Receptors Prevents Morphine-Induced Place Preference in Mice
    Blockade of o-Opioid Receptors Prevents Morphine-Induced Place Preference in Mice Tsutomu Suzuki', Michiharu Yoshiike', Hirokazu Mizoguchi', Junzo Kamei', Miwa Misawa' and Hiroshi Nagase2 'Department of Pharmacology , School of Pharmacy, Hoshi University, 2-4-41 Ebara, Shinagawa-ku, Tokyo 142, Japan 2Basic Research Laboratories , Toray Industries, Inc., 111 Tebiro, Kamakura 248, Japan Received May 12, 1994 Accepted June 18, 1994 ABSTRACT-Effects of highly selective 5-opioid receptor antagonists on the morphine-induced place preference in ddY and p,-opioid receptor deficient CXBK mice were investigated. Pretreatment with naltrin dole (NTI: a non-selective 5-opioid receptor antagonist), 7-benzylidenenaltrexone (BNTX: a selective 5, opioid receptor antagonist) or naltriben (NTB: a selective 52-opioid receptor antagonist) abolished the mor phine-induced place preference in ddY mice in a dose-dependent manner. These findings suggest that the morphine-induced place preference may be mediated by both d, and 52-opioid receptors. On the other hand, in p,-opioid receptor deficient CXBK mice, pretreatment with these selective 5-opioid receptor an tagonists did not affect the morphine-induced place preference, although pretreatment with ;3-funaltrex amine (13-FNA: a selective p-opioid receptor antagonist) significantly inhibited the morphine-induced place preference. [D-Pen 2,D-Pen5]enkephalin (DPDPE: a 0,-opioid receptor agonist) and [D-Ala2, Glu4]deltorphin (deltorphin II: a 52-opioid receptor agonist) induced a significant place preference in ddY mice, but not in CXBK mice. These results suggest that d, and 52-opioid receptors in the nucleus accumbens that are related to the DPDPE and deltorphin II-induced place preference may be dysfunctional and/or poor in CXBK mice.
    [Show full text]
  • Selective Effects of the Δ-Opioid Receptor Agonist DPDPE On
    Behavioral Neuroscience Copyright 2005 by the American Psychological Association 2005,Vol. 119,No. 2,446–454 0735-7044/05/$12.00 DOI: 10.1037/0735-7044.119.2.446 Selective Effects of the ␦-Opioid Receptor Agonist DPDPE on Consummatory Successive Negative Contrast Michael Wood,Alan M. Daniel,and Mauricio R. Papini Texas Christian University Two experiments explored the role of the opioid system in a situation involving a surprising reduction in reward magnitude: consummatory successive negative contrast. Rats received access to 32% sucrose solution (preshift Trials 1–10) followed by 4% solution (postshift Trials 11–15). Independent groups received an injection of either the vehicle or the ␦-receptor agonist [D-Ala2-,N-Me-Phe4,Gly-ol] enkephalin (DPDPE; 24 ␮g/kg). DPDPE attenuated the contrast effect when injected before Trial 11 but not when injected before Trial 12. An additional experiment showed that the attenuating effect of partial reinforcement on the recovery from contrast was reduced by DPDPE injections administered before nonreinforced preshift trials. Rats exposed in daily trials to a sweet 32% sucrose solution later cSNC situation,but none appears to be selective. For example, drank a less-sweet 4% solution significantly less often than did a Rowan and Flaherty (1987) reported that morphine (4 and 8 control group exposed to only the 4% solution (Vogel,Mikulka,& mg/kg; a nonselective opioid agonist),administered 20 min before Spear,1968). This effect,known as consummatory successive the first postshift trial significantly reduced the size of the cSNC negative contrast (cSNC),involves a sharp suppression of con- effect,without affecting consummatory behavior per se.
    [Show full text]
  • (D-Ala*)Deltorphin II: D,-Dependent Stereotypies and Stimulation of Dopamine Release in the Nucleus Accumbens
    The Journal of Neuroscience, June 1991, 17(6): 1565-l 576 (D-Ala*)Deltorphin II: D,-dependent Stereotypies and Stimulation of Dopamine Release in the Nucleus Accumbens R. Longoni,’ L. Spina,’ A. Mulas,’ E. Carboni,’ L. Garau,’ P. Melchiorri,2 and G. Di Chiaral ‘Institute of Experimental Pharmacology and Toxicology, University of Cagliari, 09100 Cagliari, Italy and 21nstitute of Medical Pharmacology, University of Rome “La Sapienza,” 00185 Rome, Italy In order to investigate the relative role of central 6- and has been implicated in the stimulant actions of systemic opiates. F-opioid receptors in behavior, the effects of (D- Morphine-like opiates stimulate DA release preferentially in the Ala*)cleltorphin II, a natural Gopioid peptide, and PL017, nucleus accumbens (Di Chiara and Imperato, 1988a) and elicit a beta-casomorphin derivative specific for mu receptors, hypermotility sensitive to blockade by the DA D, receptor an- were compared after local intracerebral and intraventricular tagonist SCH 23390 (Longoni et al., 1987a). Intra-accumbens administration. lntracerebral infusion of the two peptides was infusion of opioid peptides elicits motor stimulation, but this done bilaterally in the limbic nucleus accumbens and in the action seems independent from DA, being resistant to classic ventral and dorsal caudate putamen of freely moving rats DA-receptor antagonists (neuroleptics; Pert and Sivit, 1977; Ka- through chronic intracerebral cannulas. After intra-accum- livas et al., 1983). Moreover, the syndrome elicited by intra- bens infusion, the two peptides elicited marked but opposite accumbens opiates is biphasic, as motor stimulation is typically behavioral effects: while (o-Ala2)deltorphin II evoked dose- preceded by motor inhibition and catalepsy (Costa11et al., 1978).
    [Show full text]
  • NIDA Drug Supply Program Catalog, 25Th Edition
    RESEARCH RESOURCES DRUG SUPPLY PROGRAM CATALOG 25TH EDITION MAY 2016 CHEMISTRY AND PHARMACEUTICS BRANCH DIVISION OF THERAPEUTICS AND MEDICAL CONSEQUENCES NATIONAL INSTITUTE ON DRUG ABUSE NATIONAL INSTITUTES OF HEALTH DEPARTMENT OF HEALTH AND HUMAN SERVICES 6001 EXECUTIVE BOULEVARD ROCKVILLE, MARYLAND 20852 160524 On the cover: CPK rendering of nalfurafine. TABLE OF CONTENTS A. Introduction ................................................................................................1 B. NIDA Drug Supply Program (DSP) Ordering Guidelines ..........................3 C. Drug Request Checklist .............................................................................8 D. Sample DEA Order Form 222 ....................................................................9 E. Supply & Analysis of Standard Solutions of Δ9-THC ..............................10 F. Alternate Sources for Peptides ...............................................................11 G. Instructions for Analytical Services .........................................................12 H. X-Ray Diffraction Analysis of Compounds .............................................13 I. Nicotine Research Cigarettes Drug Supply Program .............................16 J. Ordering Guidelines for Nicotine Research Cigarettes (NRCs)..............18 K. Ordering Guidelines for Marijuana and Marijuana Cigarettes ................21 L. Important Addresses, Telephone & Fax Numbers ..................................24 M. Available Drugs, Compounds, and Dosage Forms ..............................25
    [Show full text]